Counselors in Washoe Valley, NV Accepting Medicare
9 Counselors found. Showing 1 - 9
 Alexis Henderson, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lakeshore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Mrs. Jana Marie Wellman, MFT-I Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lake Shore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Shannon Harrison Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3275 Lake Shore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Mrs. Dana M Zbella Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lakeshore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Mrs. Jennifer Lynn Obryan-taft, BSHS Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3455 Vegas Way, Washoe Valley, NV 89704 Phone: 775-470-5846 |
Ms. Patricia A Cummings Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lakeshore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-948-3435 |
Mrs. Shirley A Webster, MFT, LADC, LPC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 3275 Lakeshore Drive, Htn, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Miss Lacie L Young Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lake Shore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
Miss Nichole R Dickman Counselor Medicare: Not Enrolled in Medicare Practice Location: 3275 Lakeshore Dr, Washoe Valley, NV 89704 Phone: 775-849-3434 Fax: 775-849-3435 |
News Archive
Raptor Pharmaceutical announces Phase 2b results of DR Cysteamine trial
Raptor Pharmaceutical Corp., today announced results from a Phase 2b clinical trial of its proprietary delayed-release cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis"). The trial, conducted at the University of California, San Diego ("UCSD") General Clinical Research Center, evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of DR Cysteamine in nine cystinosis patients.
FDA announces sweeping plan to review safety of surgical staplers
The Food and Drug Administration announced a sweeping plan on Friday to review and address the safety of surgical staplers, including a new examination of seven years' worth of hidden reports highlighted Thursday in a Kaiser Health News investigation.
FDA grants final approval for Mylan's Promethazine HCl Tablets
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Promethazine Hydrochloride (HCl) Tablets USP, 12.5 mg, 25 mg and 50 mg. Promethazine HCl Tablets are used to relieve the symptoms of certain allergic reactions, such as perennial and seasonal allergic rhinitis.
Nuclear fallout-related health fears rise in Japan
Concerns regarding health risks "rose dramatically in Japan Tuesday" after officials said more radiation was released at a nuclear power plant that was damaged in the tsunami, the Associated Press reports. In an address to the nation, Prime Minister Naoto Kan said radiation had been emitted from four reactors. "The level seems very high, and there is still a very high risk of more radiation coming out," he said.
With repeal still on the table, health debate detente expected to be temporary
Although GOP interest in turning back the health law remains strong, lawmakers' face the challenge of tempering some of their rhetoric in the wake of the Tucson shootings. Meanwhile, people on both sides of the aisle say this "timeout" is likely to be only temporary.
› Verified 2 days ago